- Trials with a EudraCT protocol (193)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (79)
193 result(s) found for: Pioglitazone.
Displaying page 3 of 10.
EudraCT Number: 2011-006113-34 | Sponsor Protocol Number: XAMNPIOAP2011 | Start Date*: 2013-10-24 |
Sponsor Name:AURORA PUJOL ONOFRE | ||
Full Title: Effect of pioglitazone administred to patients with Adrenomyeloneuropathy: A phase II, Singlearm, Monocentric Trial. | ||
Medical condition: X-linked adrenoleukodystrophy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002199-14 | Sponsor Protocol Number: CLAF237A2354 | Start Date*: 2005-09-14 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multicenter, double-blind, randomized, active controlled study to compare the effect of 52 weeks treatment with vildagliptin 50 mg bid to pioglitazone 30 mg daily as add-on therapy in patients wi... | ||
Medical condition: Type II Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-009157-24 | Sponsor Protocol Number: BC21893 | Start Date*: 2009-06-29 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: Estudio multicéntrico, randomizado, doble ciego, con doble enmascaramiento, controlado frente a un comparador activo para evaluar la eficacia, seguridad y tolerancia de taspoglutida (RO5073031) co... | ||||||||||||||||||
Medical condition: Pacientes con diabetes mellitus tipo 2 Patients with Type 2 diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003360-19 | Sponsor Protocol Number: P070123 | Start Date*: 2008-11-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude de l'effet de la pioglitazone dans l'ataxie de Friedreich : étude "preuve de concept" | |||||||||||||
Medical condition: Ataxie de Friedreich | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002218-21 | Sponsor Protocol Number: 0431-068 | Start Date*: 2008-01-03 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-DOse Combination Tablet of Sitagliptin and M... | |||||||||||||
Medical condition: type II diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IS (Completed) IT (Completed) SI (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004699-38 | Sponsor Protocol Number: RCCC10 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Klinikum der Universität Regensburg | |||||||||||||
Full Title: A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alpha in metastatic, non-resectable renal clear cell carcinoma | |||||||||||||
Medical condition: To investigate the effect of an anti-inflammatory therapy consisting of pioglitazone (Actos) in combination with an angiostatic treatment with sorafenib (Nexavar) and Interferin-Alpha (Roferon) on ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003803-31 | Sponsor Protocol Number: PIO-BP | Start Date*: 2015-05-29 | |||||||||||
Sponsor Name:Hospital Universitario Araba (Sede Santiago) | |||||||||||||
Full Title: Adjunct pioglitazone IN THE TREATMENT OF BIPOLAR DISORDER. | |||||||||||||
Medical condition: Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018070-64 | Sponsor Protocol Number: 28431754DIA3012 | Start Date*: 2010-05-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagli... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) DE (Completed) PT (Prematurely Ended) FR (Completed) ES (Completed) IT (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004694-97 | Sponsor Protocol Number: KG2105255 | Start Date*: 2007-02-22 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 male and female subjects, aged 18 to... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) LV (Completed) CZ (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002768-32 | Sponsor Protocol Number: MM03 | Start Date*: 2009-06-08 | |||||||||||
Sponsor Name:Freistaat Bayern | |||||||||||||
Full Title: A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in p... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004798-60 | Sponsor Protocol Number: CL3-00780-148 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:I.R.I.S. Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonyl... | |||||||||||||
Medical condition: Type II Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001800-20 | Sponsor Protocol Number: PADBelch07 | Start Date*: 2007-08-10 |
Sponsor Name:University of Dundee | ||
Full Title: A randomised, placebo-controlled trial of the effect of pioglitazone on vascular endothelial function and novel biomarkers for macrovascular events in diabetics with established peripheral arterial... | ||
Medical condition: The study involves patients with type 2 Diabetes and Peripheral Arterial Disease.The overall objective of the research proposal is to determine the occurrence of biomarkers that typify the metaboli... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000171-15 | Sponsor Protocol Number: IMT-MRI-Trial-2006 | Start Date*: 2007-01-17 |
Sponsor Name:University Hospital of Ulm | ||
Full Title: Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with con... | ||
Medical condition: Male or female non-diabetic patients at an age between 30 and 79 years (inclusive) with a proven vascular disease defined as arteriosclerosis confirmed by presence of CAD, PAD or carotid plaques. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005849-16 | Sponsor Protocol Number: KIN001-203 | Start Date*: 2021-03-09 | |||||||||||
Sponsor Name:Kinarus AG | |||||||||||||
Full Title: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patient... | |||||||||||||
Medical condition: COVID-19 development in hospitalized patients infected with SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002271-41 | Sponsor Protocol Number: ATS K020 (D-PIO 112) | Start Date*: 2006-10-25 | |||||||||||
Sponsor Name:Takeda Pharma GmbH | |||||||||||||
Full Title: Effects of Pioglitazone in Combination with Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients with Type 2 Diabetes mellitus | |||||||||||||
Medical condition: Patients with Type 2 Diabetes mellitus and HbA1c > 6,5%, but < 8,5% and/ or fasting plasma glucose > 7 mmol/l will be eligible for the study | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000738-39 | Sponsor Protocol Number: FARM6T9CET | Start Date*: 2010-03-02 | ||||||||||||||||
Sponsor Name:Societa' Italiana di Diabetologia | ||||||||||||||||||
Full Title: EFFECTS ON INCIDENCE OF CARDIOVASCULAR EVENTS OF THE ADDITION OF PIOGLITAZONE AS COMPARED WITH A SULFONYLUREA IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN Thiazolidinediones O... | ||||||||||||||||||
Medical condition: diabetes mellitus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000815-13 | Sponsor Protocol Number: DIA-644-HOL-005-I | Start Date*: 2008-09-29 | |||||||||||
Sponsor Name:Technical University Munich | |||||||||||||
Full Title: Analysis of cerebral, renal, peripheral, and retinal hemodynamics in adults with type 2 diabetes before, during, and after administration of pioglitazone or placebo. | |||||||||||||
Medical condition: Considering the existing data, Actos (pioglitazone) is a promising candidate to improve hemodynamics of various vascular beds by positive effects on endothelial function. This study aims to analyse... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012598-37 | Sponsor Protocol Number: DUT-MD-304 | Start Date*: 2010-01-29 | |||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUTOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ON BACKGROUND TREATMENT WIT... | |||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004095-31 | Sponsor Protocol Number: ModuLung | Start Date*: 2015-07-13 | |||||||||||||||||||||
Sponsor Name:Freistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor | |||||||||||||||||||||||
Full Title: A prospective phase II, randomized multi-center trial of a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squ... | |||||||||||||||||||||||
Medical condition: locally advanced or metastatic NSCLC, who have progressed during or following a platinum-containing regimen. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005410-13 | Sponsor Protocol Number: GERP ALS | Start Date*: 2008-04-22 | |||||||||||
Sponsor Name:University Hospital of Ulm | |||||||||||||
Full Title: EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE). | |||||||||||||
Medical condition: Male or female adult patients with amyotrophic lateral sclerosis (ALS) accoring to the El Escorial Criteria for the diognosis of ALS and treated for at least 3 month with 100 mg riluzole (standard ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
